Desensitization With Belimumab in Sensitized Patients Awaiting Kidney Transplant

NCT01025193 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

8

Enrollment

OTHER

Sponsor class

Stopped has not demonstrated efficacy in primary goal

Conditions

Desensitization

Interventions

DRUG: Belimumab

Sponsor

University of Pennsylvania

Collaborators

[object Object]